Price rises drive Moldova's pharma market growth
This article was originally published in Scrip
Retail pharmaceutical sales in Moldova grew by almost 60% to $49.6 million in the first six months of this year, while the number of packs sold increased by 10%, reports Business-Credit, a Kiev-based market research firm. Imported products represented the overwhelming majority (96%) of all medicines on the market, with sales of $47.7 million (+58%).
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.